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Introduction
Retinoblastoma (RB) is the most common intraocular 
tumour of childhood.[1] No variation is seen among 
the age and gender at presentation. An estimated 
5000 new cases are reported every year. A 
relatively recent population-based cancer survey 
has reported that the age-adjusted incidence of 
RB in India alone is 1.3–12.3/million children.[2] RB 
is malignancy associated with germline or somatic 
mutation. Germline mutations can present as early 
as 1-month age. However, sporadic mutations 
are detected at approximately 24 months of 
age.[3] Leucocoria (white reflex) is the most common 
presenting sign, which is noticed when the tumour 
is still contained within the eye. When detected at 
an early age, prompt intervention can save the eye. 
However, delayed diagnosis can lead to invasion 
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Abstract
Introduction: Retinoblastoma (RB) is the most common intraocular 
malignancy arising from the developing retina and occurs in approximately 
one of every 15,000–20,000 births. With the introduction of the intra-
arterial chemotherapy (IAC), the 5-year overall survival of children with 
RB is 99%, though in low- and middle-income countries, it rarely exceeds 
35% due to limited resources and lack of expertise. The aim of this 
study was to determine the outcome of local salvage in advanced  RB. 
Materials and Methods: A retrospective analysis was conducted on 
children diagnosed with advanced RB that had local salvage therapy along 
with systemic chemotherapy from January 2015 to January 2018 at Shaukat 
Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. 
Results: Fifteen patients were included in the study, among these 10 were 
male. The median age of presentation was 20 months (range 2–40 months). 
Among participants, 11 patients had bilateral RB. Fourteen patients 
received local control along with systemic chemotherapy. Relapse disease 
was seen in 12 patients and 2-year disease-free survival (DFS) was 20%. 
Conclusion: The results of the present study suggest that centres lacking 
the resources for IAC should treat advance cases of RB with an upfront or 
early enucleation. 
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of the optic nerve and widespread metastatic 
disease.[4]
There have been many advances in the management 
of RB. These include systemic chemotherapy, 
external beam radiotherapy and intravitreal 
chemotherapy. At present, Intraophthalmic artery 
chemotherapy (OAC) is considered as the first 
line of therapy for the advance and recurrent RB.[5] 
However, in the absence of availability of OAC, 
enucleation remains the standard for the advanced 
disease.
The aim of this retrospective analysis was to 
determine the outcome of salvage treatment in 
advanced RB in a setting where OAC was not 
available.
Materials and Methods
A retrospective chart review was performed of 
patients who underwent local salvage therapy for 
the management of advanced RB Shaukat Khanum 
Memorial Cancer Hospital and Research Centre, 
Lahore, Pakistan, between January 2015 and 
January 2018. Approval from the local Institutional 
Review Board was obtained (EX-12-09-19-01).
All patients had undergone a comprehensive 
clinical assessment comprising a detailed history, 
thorough examination and clinicoradiopathological 
evaluation. This comprised magnetic resonance 
imaging (MRI) of the brain, evaluation under 
anaesthesia (EUA), bilateral bone marrow biopsy 
and cerebrospinal fluid analysis. Local staging of the 
disease was performed, based on the International 
Classification of Retinoblastoma (IRCB) [Table 1].[6] 
Group D and Group E diseases were labelled as 
locally advanced disease.
Patients that were diagnosed with advance RB were 
started on systemic chemotherapy adapted from the 
guidelines of the United Kingdom Children’s Cancer 
Table 1: International Classification of Retinoblastoma.[6]
International Classification of Retinoblastoma
Group A Small intraretinal tumour away from the fovea and disc
All tumours are 3 mm or smaller in greatest dimension, confined to the retina and
All tumours are located further than 3 mm from the foveola and 1.5 cm from the optic disc
Group B All remaining discrete tumours confined to the retina
All other tumours confined to the retina not in Group A
Tumour-associated subretinal fluid <3 mm from the tumour with no subretinal seeding.
Group C Discrete local disease with minimal subretinal or vitreous seeding
Tumour(s) are discrete
Subretinal fluid, present or past without seeding up to ¼ retina
Local fine vitreous seeding may be present close to discrete tumour.
Local subretinal seeding <3 mm (2DD) from the tumour
Group D Diffuse disease with significant vitreous and subretinal seeding
Tumour(s) may be massive or diffuse
Subretinal fluid, present or past without seeding, involving up to total retinal detachment
Diffuse or massive vitreous disease may include ‘greasy’ seeds or avascular tumour masses.
Diffuse subretinal seeding may include subretinal plaques or tumour nodules. 
Group E Presence of any one or more of the following poor prognosis features
Tumour touching the iris
Tumour anterior to anterior vitreous face involving ciliary body or anterior segment
Diffuse infiltrating retinoblastoma
Neovascular glaucoma
Opaque media from haemorrhage
Tumour necrosis with aseptic orbital cellulitis
Phthisis bulbi
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Study Group – RB working Group.[7] The initial intent 
of the treatment was globe preservation. All patients 
were started on JOE chemotherapy. This consists 
of vincristine (1.5 mg/m2), carboplatin (600 mg/m2) 
and etoposide (300 mg/m2). Patients received 
from 4 to 10 cycles of chemotherapy depending 
on the response to treatment. The EUA was done 
after an average of 2 cycles of chemotherapy. In 
addition to systemic chemotherapy, patients were 
also given local therapy. This consisted of laser 
therapy; cryotherapy; intravitreal chemotherapy 
(melphalan at dose 20–30 mg and methotrexate 
[MTX] 400 mg)[8] and periocular chemotherapy 
(topotecan 0.5–2 mg).[9] Disease response was 
assessed at the end of the therapy with MRI study 
and EUA (patients who had vitreous seeding/local 
minimal disease were started on local therapy). 
Patients with relapsed disease were treated on 
second-line chemotherapy – ifosfamide, vincristine 
and doxorubicin (IVAD) (vincristine 1.5 mg/m2, 
doxorubicin 25 mg/m2 and ifosfamide 3000 mg/m2).[10] 
Patients treated will be followed until the age of 
10 years.
Statistical analysis was performed using SPSS 
software (Version 22.0; SPSS, Chicago, IL). 
Descriptive statistics were reported as frequencies 
and percentages for quantitative data. Fischer’s exact 
test as used to determine the statistical association 
between the extent of disease and outcome of the 
therapy. P < 0.05 was statistically significant. Disease-
free event was calculated from the end of treatment 
until the first event of disease progression or relapse.
Results
A total of 15 patients met the inclusion criteria. 
The median age of presentation was 20 months 
(range 2–40 months). About 66.7% (n = 10) of the 
patients were male. The most common presenting 
symptom was leucocoria. It was present in 66.7% 
(n = 10) of patients. This was followed by the 
presence of squint in 20% (n = 3) of patients. 
Unilateral advance disease was seen in four patients, 
whereas bilateral disease was present in 11 patients. 
Group D or E was seen in 12 patients (80%), 
whereas the rest of the patients had Group B or C. 
The association between the involvement of globe 
(unilateral or bilateral) and stage of the disease was 
not statistically significant (P > 0.05). These results 
are summarised in Table 2.
Laser therapy was done in 10 patients (66.7%) along 
with systemic chemotherapy. However, due to 
poor therapeutic response, six patients underwent 
additional treatment in the form of cryotherapy. 
Intravitreal melphalan was administered to 3 
patients (20%) secondary to persistent vitreous 
seeding. Likewise, two patients received intravitreal 
MTX. Periocular topotecan was given to four patients 
and intravitreal topotecan was administered to 
one patient. Systemic melphalan for globe salvage 
was administered to two patients. There was no 
statistically significant association present between 
the severity of disease and the outcome of the 
treatment modalities (P > 0.05).
Relapse of intraocular RB was seen in 12 patients 
(80%). Among these, nine underwent enucleation, 
one was started on second-line chemotherapy – 
IVAD and two died before any intervention could 
be offered. Two-year disease-free survival (DFS) 
was calculated to be 20%. None of the patients had 
distant metastasis or secondary malignancies.
Discussion
RB is the most common intraocular malignancy in 
children that can lead to death within 1–2 years, if left 
Table 2: Summary of patient characteristics
Clinical parameter Subtype n (%)
Age <12 months 6 (40)
>12 months 9 (60)
Gender Male 10 (66.7)
Female 5 (33.3)
Disease involvement Unilateral 4 (26.7)
Bilateral 11 (73.3)
Clinical presentation Leucocoria 10 (66.7)
Strabismus 3 (20)
Proptosis 2 (13.3)
Disease stage Group B or C 3 (20)
Group D or E 12 (80)
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untreated.[11] The aim of this study was to determine 
the outcome of salvage treatment in advanced RB. 
A total of 15 patients were included in the present 
investigation. Two-year DFS was found to be 
20%. Among patients that had relapse of RB, 75% 
underwent enucleation. No statistically significant 
association was present between the severity of the 
disease and the outcome of treatment modalities.
Over the past years, intra-arterial chemotherapy (IAC) 
has been developed as a promising alternative instead 
of systemic chemotherapy for the management 
of advanced and refractory RB. The main reason 
behind the popularity of IAC is the avoidance of 
enucleation.[12] Majority of patients in the present 
study fell into either Group D or E as per IRCB. This is 
likely due to delayed presentation to the health-care 
facility. Similar observations have been made by other 
investigators working in developing countries.[13,14]
In the present study, three patients received 
intravitreal (IVit) melphalan in addition to systemic 
therapy. All these patients had recurrence of 
disease and underwent enucleation. This is contrary 
to the findings reported by others. Previously, it has 
been shown that patients receiving IVit along with 
systemic chemotherapy have good outcomes in 
terms of globe salvage.[11]
Prior investigations have reported beneficial 
outcomes with the use of high-dose periocular 
topotecan. These effects have been consistent even 
in the presence of vitreous seeding.[15] In the present 
study, three patients received periocular topotecan 
along with systemic chemotherapy. However, 
two of these three patients had recurrence and 
underwent enucleation. Nonetheless, in one 
patient, globe was salvaged. This is likely because 
these two patients had relatively advanced disease 
(Group D or E stage).
The use of periocular chemotherapy (carboplatin), 
as monotherapy is not recommended. Nonetheless, 
when used in combination with other modalities, 
it has shown to result in significant improvements 
without any major acute or chronic complications.[16] 
In the present series, one patient with persistent 
disease received periocular carboplatin along with 
systemic chemotherapy. However, this patient died 
due to relapse of disease.
The outcome of salvage therapy with IVit 
chemotherapy and/or periocular chemotherapy 
was only 20%. Based on the findings of the present 
investigation, we recommend upfront or early 
enucleation for patients with advanced disease 
in centres that have limited resources or limited 
expertise in IAC. One of the major limitations 
of the present study is that it is a retrospective 
analysis. It was not possible to control clinical visits, 
number and type of chemotherapy sessions and 
local treatments or severity of disease. In addition, 
due to the nature of the study design, it may 
result in magnification of the positive or negative 
responses. Nonetheless, in this study, we used 
records from all the hospital visits to reduce risk of 
recall or reporting bias. Future investigations on 
the effectiveness of early or late enucleation for 
patients with advanced disease are recommended.
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